Sign in
Taking people in New ZealandPhase 1/2

Testing NXT007 in males with severe or moderate hemophilia A

Tests NXT007 for safety and effect in males aged 2 to 59 with hemophilia A.

Key facts

Who runs it
Hoffmann-La Roche
Where
Auckland, New ZealandSee the siteAlso in 5 other countries, 13 sites
Registry title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
21 Sept 2023
Expected to end
11 Dec 2033
Type of study
Interventional, 6 groups
Treatments tested
  • NXT007
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for males with severe or moderate hemophilia A, with or without FVIII inhibitors, who are aged 2 to 59 years.

Age
2 to 59 years
Sex
Males only
Disease stage
Severe (FVIII:C <1 IU/dL) or moderate (FVIII:C ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A, with or without inhibitors against FVIII
Earlier treatment
People with FVIII inhibitors must use rFVIIa or be willing to switch to it for bleeds. Past immune tolerance induction must have been completed at least 5 years before screening. No prior gene therapy.
Biomarker or test result
FVIII inhibitor test results from the past must be available. FVIII:C below 1 IU/dL (severe) or 1 to 5 IU/dL (moderate).

Main reasons for not taking part

  • Other bleeding disorders besides congenital hemophilia A
  • Ongoing or planned immune tolerance induction therapy
  • Current or past treatment for blood clot disease, or signs of it
  • Known HIV infection with CD4 counts <200 cells/μL
  • Abnormal heart rhythm tests or risk factors for dangerous heart rhythms

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Diagnosis of severe (Factor VIII coagulant activity [FVIII:C] <1 IU/dL) or moderate (FVIII:C ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A with or without inhibitors against FVIII
  • Participants with FVIII inhibitors: participants using recombinant activated factor VII (rFVIIa) or willing to switch to rFVIIa as primary bypassing agent for the treatment of breakthrough bleeds, trauma, or procedures
  • Historic local FVIII inhibitor test results being available during screening to confirm any previous inhibitor history and current status
  • Participants who previously successfully completed immune tolerance induction (ITI) must have done so at least 5 years before screening and must have no evidence of inhibitor recurrence (permanent or temporary) since. FVIII tolerance defined as <0.6 Bethesda unit (BU)/mL (<1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and in vivo recovery >66%
  • Documentation of number and type of bleeding episodes in the last 24 weeks prior to enrollment
  • Adequate hematologic function, defined as platelet count ≥100,000 cells/μL and hemoglobin ≥11 g/dL at the time of screening
  • Adequate hepatic function defined as total bilirubin ≤1.5× age-adapted upper limit of normal (ULN) (excluding Gilbert syndrome) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× age-adapted ULN at the time of screening, and no clinical signs or known laboratory/radiographic evidence consistent with cirrhosis. For patients with Gilbert syndrome, bilirubin should be <4 mg/dL or 68.4 umol/L at the time of screening
  • For Part 1 only: Adequate renal function, defined as serum creatinine ≤2.5× age-adapted ULN and calculated creatinine clearance ≥30 mL/min by Cockroft-Gault formula
  • For Part 2 only: Adequate renal function, defined as serum creatinine ≤1.5× age-adapted ULN. When the serum creatinine is ≥1.5× ULN, creatinine clearance by Bedside Schwartz formula must be >70 mL/min/1.73m\^2
  • Willingness and ability to comply with schedules visits, treatment plans, laboratory tests, and other study procedures

Who cannot take part

  • Ongoing or planned ITI therapy
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • For Part 1 only: Previous or concomitant malignancies or leukemia
  • Receipt of any of the following:; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration or normalization of targeted parameters (e.g., anti-thrombin), whichever is longer; ii) A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; iii) Any other investigational drug currently being administered or planned to be administered; iv) Prior gene therapy or gene therapy planned to be administered; v) Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use during the study, with the exception of anti-retroviral therapy to treat HIV
  • History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third -degree atrioventricular heart block), including atrial fibrillation or evidence of prior myocardial infarction
  • Inherited or acquired bleeding disorders other than congenital hemophilia A
  • At high risk for thrombotic microangiopathy (TMA), including past personal or family history of TMA, in the investigator's judgment
  • For Part 1 only: Personal history of ischemic heart disease, cerebrovascular disease, or diabetes mellitus
  • Other conditions (e.g., autoimmune conditions such as Systemic Lupus erythematosus and other systemic inflammatory disorders) that may currently increase the risk of bleeding or thrombosis
  • History of clinically significant allergies
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy and to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to Chinese hamster ovary cell products or to excipient content
  • Known HIV infection with CD4 counts <200 cells/μL
  • QT interval corrected through use of Fridericia's formula (QTcF) >450 ms demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well known to prolong the QT interval
  • For Part 1 only: Strong family history of ischemic heart disease or cerebrovascular disease (i.e., first degree relatives such as parents, full siblings, or children): male relatives diagnosed under the age of 55 years and females under the age of 65 years
  • Protein C activity, protein S free antigen, or anti-thrombin III activity levels below the lower limit of the reference range at screening

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 2 and 59 years old?

This trial is currently available in New Zealand.

Also in 5 other countries, 13 sites

  • Auckland Cancer Trial CentreAuckland, New ZealandTaking people

About the trial

What the trial wants to find out

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts:

Read full original descriptionShow less

* Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors.

The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.

The 6 groups in the trial

  • Part 1: Cohort 1 - NXT007 Dose Level 1 (Low)Treatment being tested

    Treatment: NXT007

  • Part 1: Cohort 2 - NXT007 Dose Level 2Treatment being tested

    Treatment: NXT007

  • Part 1: Cohort 3 - NXT007 Dose Level 3Treatment being tested

    Treatment: NXT007

  • Part 1: Cohort 4 - NXT007 Dose Level 4Treatment being tested

    Treatment: NXT007

  • Part 1: Cohort 5 - NXT007 Dose Level 5 (High)Treatment being tested

    Treatment: NXT007

  • Part 2: Cohort A - NXT007Treatment being tested

    Treatment: NXT007

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Plain-language title
Testing NXT007 in males with severe or moderate hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05987449, who can take part
Record updated
5 November 2026